Thalassemia Major: Transfusion and Chelation or Transplantation

Publication date: Available online 20 June 2017
Source:Hematology/Oncology and Stem Cell Therapy
Author(s): Said Yousuf Mohamed
Thalassemia is the most common monogenic hematologic disease that affects millions in the world and kills thousands of patients every year.Without transfusion or transplantation, patients with thalassemia major are expected to die within months of diagnosis. However, long-term transfusion and chelation therapy is highly challenging for many developing countries where the disease is prevalent, representing a major and unsustainable health burden.Stem cell transplantation is the only cure for thalassemia. It has witnessed major developments that have made it less toxic, more successful, and feasible for a larger number of patients with diverse comorbidities and from a wider range of donors. Advances in human leukocyte antigen typing have greatly refined alternate donor selection with results of matched unrelated donors similar to matched sibling donors.Novel strategies like haploidentical and cord blood transplantation have increased the possibility of patients with no healthy donor to get a better opportunity to survive and avoid chronic transfusion complications.Cost effectively, transplantation should be considered the primary treatment of choice in the presence of a suitable related or unrelated donor and at centers with a satisfactory experience in the field of transplantation and particularly, in managing those with thalassemia. Despite some complications such as graft versus host disease and late conditioning effects, the overall improvement in the quality of life of thalassemia is difficult to deny.Unfortunately, the number of transplants for thalassemia represents only a minority of all transplants conducted globally. Moreover, the essential requirement for transplants for thalassemia in limited-resources countries should mandate the transplant societies, including Worldwide Network for Blood and Marrow Transplantation, to collaborate to help initiate and support specialized transfusion and transplant programs for managing thalassemia.



http://ift.tt/2rCaUib